Physician profile
Shrina Modi
NPI 1417425877
$7,853.26
in general payments reported to CMS, 2019-2025
29 companies · $3,511 in 2025
The $3,511 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $314 · 2022: $317 · 2023: $1,675 · 2024: $2,037 · 2025: $3,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,935 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,125 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,935.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,125.00 |
| Education | $162.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $2,464.23 | 2024-2025 | Ibsrela |
| Abbvie INC. | $1,655.62 | 2021-2025 | |
| Janssen Biotech, INC. | $614.14 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $524.48 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $323.86 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $233.93 | 2023-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $227.72 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $198.51 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $155.42 | 2021-2024 | Rebyota |
| Madrigal Pharmaceuticals | $144.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $140.01 | 2024-2025 | Voquezna |
| Nuvasive, INC. | $136.90 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $134.05 | 2024 | Dupixent |
| Axonics, INC. | $119.24 | 2023 | Bulkamid |
| Janssen Scientific Affairs, LLC | $100.78 | 2024 | Tremfya |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $99.35 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $86.82 | 2023-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $70.93 | 2021-2023 | |
| Braintree Laboratories, INC. | $62.98 | 2021-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $62.60 | 2023-2025 | Ocaliva |
| Celgene Corporation | $60.98 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $59.33 | 2024-2025 | Iqirvo, Bylvay |
| Exact Sciences Corporation | $54.66 | 2023 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $32.15 | 2023 | Idacio |
| Novo Nordisk INC | $31.38 | 2023-2025 | Wegovy |
| Celltrion USA INC. | $16.98 | 2024 | Zymfentra |
| Redhill Biopharma INC. | $15.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.57 | 2024 | Givlaari |
| Sandoz INC. | $13.39 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrina Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.